| Public policies |
 |
|
|
Download |
| |
|
|
|
|
GSK access and developing countries
|
|
|
| The treatment of children living with HIV in developing countries |
|
|
|
PDF (115Kb) |
| US President’s Emergency Plan for AIDS Relief (PEPFAR) |
|
|
|
PDF (96Kb) |
| Cervical cancer prevention |
|
|
|
PDF (70Kb) |
| Clinical trials in the developing world |
|
|
|
PDF (91Kb) |
| IP and access to medicines in developing countries |
|
|
|
PDF (89Kb) |
| Technology transfer, capacity building and developing countries |
|
|
|
PDF (174Kb) |
| WHO prequalification scheme for ARVs |
|
|
|
PDF (75Kb) |
|
|
|
|
|
| GSK and research & development |
|
|
| Cloning technologies and stem cell research |
|
|
|
PDF (77Kb) |
| The care and ethical use of animals in research |
|
|
|
PDF (78Kb) |
| The role of transgenic animals in biomedical research |
|
|
|
PDF (128Kb) |
| Disclosure of clinical trial information |
|
|
|
PDF (104Kb) |
Use of Non-human Primates (NHPs) in the Discovery and Development of Medicines and Vaccines
|
|
|
|
PDF (81Kb) |
The use of great apes in research
|
|
|
|
PDF (56Kb) |
|
|
|
|
|
| GSK and intellectual property |
|
|
| Evergreening |
|
|
|
PDF (102Kb) |
| Compulsory licences |
|
|
|
PDF (82Kb) |
| Gene patenting |
|
|
|
PDF (74Kb) |
| Proposals for a disclosure in patent applications |
|
|
|
PDF (91Kb) |
| Voluntary licensing of ARVs |
|
|
|
PDF (79Kb) |
| Regulatory data protection |
|
|
|
PDF (159Kb) |
|
|
|
|
|
| GSK and the environment |
|
|
| Climate change |
|
|
|
PDF (56Kb) |
| Hazardous chemical management |
|
|
|
PDF (68Kb) |
| Ozone depletion and metered-dose inhalers for asthma |
|
|
|
PDF (73Kb) |
| Pharmaceuticals in environment |
|
|
|
PDF (69Kb) |
| GSK and REACH |
|
|
|
PDF (50Kb) |
| GSK and the convention on biological diversity |
|
|
|
PDF (81Kb) |
| The impact of climate change on health |
|
|
|
PDF (75Kb) |
|
|
|
|
|
| GSK and public health |
|
|
| The provision by the pharma industry of information to patients |
|
|
|
PDF (106Kb) |
| Counterfeiting of healthcare products |
|
|
|
PDF (74Kb) |
Pharmacovigilance
|
|
|
|
PDF (93Kb) |
Paediatric medicines
|
|
|
|
PDF (137Kb) |
|
|
|
|
|
| GSK and competitiveness |
|
|
| Competitiveness and investment criteria |
|
|
|
PDF
(76Kb) |
| Key aspects of a sustainable healthcare system |
|
|
|
PDF (128Kb) |
|
|
|
|
|
| GSK pricing, reimbursement and market access |
|
|
| Pricing and reimbursement |
|
|
|
PDF (93Kb) |
| Health technology assessments |
|
|
|
PDF (107Kb) |
| Incremental innovation |
|
|
|
PDF (77Kb) |
|
|
|
|
|
| GSK and other issues |
|
|
| Marketing practices |
|
|
|
PDF (93Kb) |
| Product donations |
|
|
|
PDF (135Kb) |
Back to top
